42060-83-3

Usage

Uses

Used in Pharmaceutical Industry:
BIPHENYL-4-YL-PIPERIDIN-4-YL-METHANONE is used as a key intermediate in the synthesis of various pharmaceuticals for its potential to target different biological pathways. Its unique structure allows it to be a versatile building block in drug development, contributing to the creation of novel therapeutic agents.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, BIPHENYL-4-YL-PIPERIDIN-4-YL-METHANONE serves as a structural component for the design and synthesis of new drug candidates. Its presence in molecular structures can influence the pharmacological properties of the resulting compounds, making it an important tool for researchers and chemists in exploring a diverse range of applications.

InChI:InChI=1/C18H19NO/c20-18(17-10-12-19-13-11-17)16-8-6-15(7-9-16)14-4-2-1-3-5-14/h1-9,17,19H,10-13H2

Upstream product

• 53220-41-0 4-(4-chlorobenzoyl)piperidine 
• 209808-06-0 tert-butyl 4-(4-chlorobenzoyl)piperidine-1-carboxylate 

Downstream Products

• 64671-37-0 biphenyl-4-yl-[1-(2-indol-3-yl-ethyl)-piperidin-4-yl]-methanone 

Relevant academic research and scientific papers

Structural Optimization of 4-Chlorobenzoylpiperidine Derivatives for the Development of Potent, Reversible, and Selective Monoacylglycerol Lipase (MAGL) Inhibitors

Monoacylglycerol lipase (MAGL) inhibitors are considered potential therapeutic agents for a variety of pathological conditions, including several types of cancer. Many MAGL inhibitors are reported in literature; however, most of them showed an irreversible mechanism of action, which caused important side effects. The use of reversible MAGL inhibitors has been only partially investigated so far, mainly because of the lack of compounds with good MAGL reversible inhibition properties. In this study, starting from the (4-(4-chlorobenzoyl)piperidin-1-yl)(4-methoxyphenyl)methanone (CL6a) lead compound that showed a reversible mechanism of MAGL inhibition (Ki = 8.6 μM), we started its structural optimization and we developed a new potent and selective MAGL inhibitor (17b, Ki = 0.65 μM). Furthermore, modeling studies suggested that the binding interactions of this compound replace a structural water molecule reproducing its H-bonds in the MAGL binding site, thus identifying a new key anchoring point for the development of new MAGL inhibitors.

Benzoylpiperidylalkylindoles

New benzoylpiperidylalkylindoles and related compounds possessing tranquilizing, anti-hypertensive and analgesic properties and a process for the preparation thereof are described.